Hope is for everyone.

We want every patient

to become a

Cancer Survivor.

Join our worldwide Community

Co-founded by

Four outliers
Two outliers
Two outliers
Three outliers

NEWS

OUR MISSION

Oncology players usually look at the biology of the 97% of patients who die from the most lethal Cancers.

We focus on the miraculous 3% of patients who do survive.

They are the

Outliers.

patient-1
patient-2
patient-3
patient-4
patient-5
patient-6
patient-7
patient-8
patient-9
patient-10
patient-11
Our_mission_Outliers_picture_1
patient-13
patient-14
patient-15
patient-16
patient-17
patient-18
patient-19
patient-20
patient-21
patient-22
patient-23
patient-24
patient-25
patient-26
patient-27
Our_mission_Outliers_picture_2
patient-29
patient-30
patient-31
patient-32
patient-33
patient-34
patient-35
patient-36
patient-37
patient-38
patient-39
patient-40
patient-41
patient-42
patient-43
patient-44
patient-45
patient-46
patient-47
patient-48
patient-49
patient-50
patient-51
patient-52
patient-53
patient-54
Our_mission_Outliers_picture_3
patient-56
patient-57
patient-58
patient-59
patient-60
patient-61
patient-62
patient-63
patient-64
patient-65
patient-66
patient-67
patient-68
patient-69
Our_mission_Outliers_picture_4
transition

Patients with Cancer who respond exceptionally well to therapy may have molecular changes in their tumors that explain their response.

A comprehensive analysis of these Outliers may help to contribute to the development of potential new treatments.

analyse-1
analyse-2
WHAT WE DO

Cure51 focuses on patients

who have survived some of the most lethal Cancers.

brain-picto

Glioblastoma

IDH-wt (GBM)

WWD_patient1
poumon-picto

ES-SCLC

Lung Cancer
Extensive stage

WWD_patient1
pancreas-picto

PDAC

Metastatic pancreatic
Ductal adenocarcinoma

WWD_patient1
transition
OUR NETWORK

We are a TechBio company co-founded with
leading international oncology
centers and researchers from over 36 countries.

Africa_continentAmerica_continentAsia_continentEurope_continentRussiaAustralie

The Americas

  • Argentina
  • Bolivia
  • Brazil
  • Canada
  • Columbia
  • Costa-Rica
  • Mexico
  • Peru
  • USA

Europe

  • Austria
  • Bulgaria
  • Czech Republic
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Greece
  • Italy
  • Netherland
  • Norway
  • Luxembourg
  • Portugal
  • Poland
  • Romania
  • Spain
  • Slovenia
  • Sweden
  • Switzerland
  • Turkey
  • United Kingdom

Africa

  • Kenya
  • Morocco
  • Nigeria
  • South Africa
  • Tanzania
  • Tunisia

Asia & Middle-East

  • Israel
  • India
  • Japan
  • Jordan
  • Pakistan
  • Taiwan
  • Thailand
transition
WE ARE A TECHBIO COMPANY

Our proprietary Discovery Platform is a hub
to organize, analyze and discover novel therapeutic targets.

We are building a unique clinical and multi-omics database of Outliers across all continents.

Our computational biology team works with our scientific partners to discover multimodal signatures and create a library of robust targets contributing to the design of best-in-class drugs.

We develop precision medicine tools in order to deliver actionable insights to discover novel therapeutics.

OUR SCIENTIFIC LEADERS

Our Scientific Steering Committee
includes world-renowned oncologists.

We are Cure51.

Hope is for everyone.

About UsPressCareersContact Us
FacebookInstagramLinkedInManage Cookie
© 2024 CURE51, All Rights Reserved